Table 1.
Baseline demographic and clinical characteristics of study participants
| Characteristic | CHR Not Converted (CHR− ; N=33) |
CHR Converted (CHR+; N=21) |
HC (N = 51) |
F/t/X2 statistic, p- value |
|---|---|---|---|---|
| Demographic Characteristics | ||||
| Age at examination, mean (± SD) |
16.97 (3.4) | 17.3 (4.4) | 16.2 (2.7) | F=1.13, p=.33 |
| % Female (N) | 36% (12) | 19% (4) | 39% (20) | η2=2.8, p =.25 |
| IQ a | 106.9(17.6) | 104.3 (14.4) | 111.5 (13.1) | F=1.59, p=.21 |
| Parental Education, mean (± SD) |
14.7 (3.7) | 15.0 (3.4) | 15.6 (3.3) | F=.28, p=.76 |
| Race/Ethnicity %Caucasian (N) |
61% (20) | 57% (12) | 49% (25) | η2=11.79, p =.30 |
| % Asian (N) | 3% (1) | 14% (3) | 8% (4) | |
| % African-American (N) |
3% (1) | 5% (1) | 14% (7) | |
| % Hispanic/ Latino (N) |
24% (8) | 19% (4) | 16% (8) | |
| % Mixed Race/ Other (N) |
9% (3) | 5% (1) | 14% (7) | |
| Clinical Characteristics | ||||
| GAF score, mean (± SD)b |
43.4 (11.0) | 37.4 (14.3) | 79.3 (14.1) | F=58.6, p<.001 |
| SOPS Mean Total Positive Symptom score (±SD) |
13.2 (3.9) | 14.3 (4.8) | N/A | t=0.77, p=.38 |
| Current Atypical Antipsychotic Use, n (%) |
6 (18%) | 4 (19%) | N/A | η2=.006, p=.94 |
| Current Mood Stabilizer Use, n (%) |
3 (9%) | 4 (19%) | N/A | η2=1.13, p=.29 |
| Current SSRI Use, n (%) |
9 (27%) | 3 (14%) | N/A | η2=1.25, p=.26 |
Note: SSRI = selective serotonin reuptake inhibitor.
a
IQ Estimate based on Wechsler Abbreviated Scale of Intelligence (WASI)
b
Global Assessment of Functioning (GAF) scores did not differ significantly between clinical high-risk converters (CHR+), and clinical high-risk non-converters (CHR−) (p=.11).